Sanleng Wan inhibits endometriosis progression by regulating sphingolipid metabolism via the S1P/S1PR1-Akt axis based on serum metabolomics and network pharmacology

article OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
AI-generated summary by claude@2026-06, 2026-06-09

This study investigates how Sanleng Wan regulates sphingolipid metabolism through the S1P/S1PR1-Akt axis to inhibit endometriosis progression, using serum metabolomics and network pharmacology.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Drugs, Chinese Herbal Drugs, Chinese Herbal Drugs, Chinese Herbal Drugs, Chinese Herbal Drugs, Chinese Herbal Drugs, Chinese Herbal Drugs, Chinese Herbal Drugs, Chinese Herbal Drugs, Chinese Herbal Drugs, Chinese Herbal Drugs, Chinese Herbal Drugs, Chinese Herbal Drugs, Chinese Herbal Drugs, Chinese Herbal Drugs, Chinese Herbal Drugs, Chinese Herbal Drugs, Chinese Herbal Drugs, Chinese Herbal Endometriosis Endometriosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (87)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-26T00:31:20.206735+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK